IMMUNE REACTIVITY AND ONCOGENIC VIRUS INFECTIONS
IMMUNE REACTIVITY AND ONCOGENIC VIRUS INFECTIONS
批准号:
3163647
负责人:
Martin S. Hirsch
金额:
$14.05万
依托单位国家:
美国
项目类别:
财政年份:
1979
资助国家:
美国
项目状态:
已结题
起止时间:
1979-06-01 至 1989-05-31
关键词:
Alphaherpesvirinae B lymphocyte Behcet's syndrome Betaherpesvirinae Retroviridae T lymphocyte autoimmune disorder communicable disease diagnosis cryopreservation human tissue immunofluorescence technique immunopathology diagnosis immunosuppression interferons kidney transplantation latent virus infection leukemia leukocyte activation /transformation leukocyte antigen typing microorganism immunology monoclonal antibody mononucleosis neoplasm /cancer genetics neoplasm /cancer immunodiagnosis neutrophil oncogenic virus pregnancy immunology pregnancy infection rapid diagnosis systemic lupus erythematosus tissue /cell culture viral carcinogenesis virus infection mechanism virus replication
中文摘要
病毒-白细胞相互作用对感染的结果至关重要,
潜在致癌病毒。 白细胞限制了两者的复制
病毒和由病毒转化的细胞。 然而,病毒也可能
在白细胞中复制并改变其功能,抑制有效的
反应 该提案将研究潜在的
致癌人类疱疹病毒与人类白细胞。
巨细胞病毒是人类疾病的主要原因,作为致畸剂,
输血或免疫抑制后的机会性病原体,
也可能是致癌物质 我们已经证明CMV具有强有力的
对白细胞功能免疫抑制作用。 这种机制
将探索CMV诱导的低反应性。 的功能评定
特定的白细胞亚群及其相互作用将在
体内和体外。 将尝试纠正或重建
CMV诱导的缺陷性白细胞反应。 CMV-白细胞相关性将
也可用于帮助开发CMV伪源的快速诊断检测
感染的粒细胞中。
单纯疱疹病毒也可能与人类有复杂的相互作用
白细胞 我们建立了单纯疱疹病毒持续感染的动物模型
感染人T淋巴母细胞。 这种持续性感染可能是
生产性或非生产性,取决于体外操作。
添加抗病毒药物(抗体、干扰素、阿昔洛韦)或
温度升高可导致非生产性感染。 去除
抗病毒药、降低温度、添加植物血凝素或
5-氮杂胞苷可诱导生产性感染。 的机制
这些事件将在体外进行探索,并将尝试
确定甲基化在维持
非生产性感染。 原位分子杂交技术将
用于确定在感染期间被感染的细胞数量。
生产性和非生产性感染。 同样的技术将被用于
调查最近的建议,某些人类疾病,例如,
白塞氏综合征与淋巴细胞携带潜伏性疱疹有关
单纯DNA 我们的疱疹模型也将用于探索相互作用
抗病毒药物和持续性感染之间的联系
英文摘要
Virus-leukocyte interactions are critical to the outcome of infections with
potentially oncogenic viruses. Leukocytes limit the replication of both
viruses and cells transformed by viruses. However, viruses may also
replicate in leukocytes and alter their function, inhibiting an effective
response. This proposal will study the interactions of potentially
oncogenic human herpesviruses with human leukocytes.
Cytomegalovirus is a major cause of human disease, as a teratogen,
opportunistic pathogen following blood transfusions or immunosuppression,
and as a possible oncogen. We have demonstrated that CMV has a potent
immunosuppressive effect onleukocyte function. The mechanisms of this
CMV-induced hyporesponsiveness will be explored. Functional evaluation of
specific leukocyte subsets and their interactions will be undertaken in
vivo and in vitro. Attempts will be made to correct or reconstruct
CMV-induced defective leukocyte responses. CMV-leukocyte associations will
also be exploited to help develop rapid diagnostic assays for CMV artigens
in infected granulocytes.
Herpes simplex virus may also have complex interactions with human
leukocytes. We have established a model of herpes simplex virus persistent
infection of human T lymphoblasts. This persistent infection can either be
productive or non-productive, depending on manipulations in vitro.
Addition of antiviral agents (antibody, interferon, acyclovir) or
temperature elevation can result in non-productive infection. Removal of
antivirals, lowering of temperature, addition of phytohemagglutinin or
5-azacytidine can induce productive infection. The mechanisms underlying
these events will be explored in vitro, and attempts will be made to
determine the importance of methylation in the maintenance of
non-productive infections. In situ molecular hybridization techniques will
be used to determine the numbers of cells that are infected during
productive and non-productive infections. The same techniques will be used
to investigate the recent suggestion that certain human diseases, e.g.
Behcet's syndrome, are associated with lymphocytes carrying latent herpes
simplex DNA. Our herpes model will also be used to explore interactions
between antiviral agents and persistent infections.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
COMBINATION ANTI-HIV THERAPY, PATHOGENESIS AND IMMUNITY
-
批准号:6532861
-
项目类别:
-
资助金额:$36.98万
-
财政年份:2000
-
负责人:Martin S. Hirsch
-
依托单位:
COMBINATION ANTI-HIV THERAPY, PATHOGENESIS AND IMMUNITY
-
批准号:6630349
-
项目类别:
-
资助金额:$38.93万
-
财政年份:2000
-
负责人:Martin S. Hirsch
-
依托单位:
COMBINATION ANTI-HIV THERAPY, PATHOGENESIS AND IMMUNITY
-
批准号:6214372
-
项目类别:
-
资助金额:$38.85万
-
财政年份:2000
-
负责人:Martin S. Hirsch
-
依托单位:
COMBINATION ANTI-HIV THERAPY, PATHOGENESIS AND IMMUNITY
-
批准号:6374707
-
项目类别:
-
资助金额:$38.93万
-
财政年份:2000
-
负责人:Martin S. Hirsch
-
依托单位:
NEUROLOGY AGENDA
-
批准号:6099286
-
项目类别:
-
资助金额:$19.5万
-
财政年份:1999
-
负责人:Martin S. Hirsch
-
依托单位:
OUTCOMES COMMITTEE AGENDA
-
批准号:6099290
-
项目类别:
-
资助金额:$19.5万
-
财政年份:1999
-
负责人:Martin S. Hirsch
-
依托单位:
IMMUNOLOGY AND IMMUNE BASED THERAPY AGENDA
-
批准号:6099287
-
项目类别:
-
资助金额:$19.5万
-
财政年份:1999
-
负责人:Martin S. Hirsch
-
依托单位:
PHARMACOLOGY AGENDA
-
批准号:6099288
-
项目类别:
-
资助金额:$19.5万
-
财政年份:1999
-
负责人:Martin S. Hirsch
-
依托单位:
HIV DISEASE RESEARCH AGENDA
-
批准号:6099284
-
项目类别:
-
资助金额:$19.5万
-
财政年份:1999
-
负责人:Martin S. Hirsch
-
依托单位:
WOMEN'S HEALTH AGENDA
-
批准号:6099289
-
项目类别:
-
资助金额:$19.5万
-
财政年份:1999
-
负责人:Martin S. Hirsch
-
依托单位:
OUTREACH AGENDA
-
批准号:6099291
-
项目类别:
-
资助金额:$19.5万
-
财政年份:1999
-
负责人:Martin S. Hirsch
-
依托单位:
CORE--ADVANCED TECHNOLOGY LABORATORIES
-
批准号:6099292
-
项目类别:
-
资助金额:$19.5万
-
财政年份:1999
-
负责人:Martin S. Hirsch
-
依托单位:
COMPLICATIONS OF HIV DISEASE AGENDA
-
批准号:6099285
-
项目类别:
-
资助金额:$19.5万
-
财政年份:1999
-
负责人:Martin S. Hirsch
-
依托单位:
COMPLICATIONS OF HIV DISEASE AGENDA
-
批准号:6267885
-
项目类别:
-
资助金额:$19.13万
-
财政年份:1998
-
负责人:Martin S. Hirsch
-
依托单位:
PHARMACOLOGY AGENDA
-
批准号:6267888
-
项目类别:
-
资助金额:$19.13万
-
财政年份:1998
-
负责人:Martin S. Hirsch
-
依托单位:
WOMEN'S HEALTH AGENDA
-
批准号:6267889
-
项目类别:
-
资助金额:$19.13万
-
财政年份:1998
-
负责人:Martin S. Hirsch
-
依托单位:
CORE--ADVANCED TECHNOLOGY LABORATORIES
-
批准号:6267892
-
项目类别:
-
资助金额:$19.13万
-
财政年份:1998
-
负责人:Martin S. Hirsch
-
依托单位:
NEUROLOGY AGENDA
-
批准号:6267886
-
项目类别:
-
资助金额:$19.13万
-
财政年份:1998
-
负责人:Martin S. Hirsch
-
依托单位:
OUTCOMES COMMITTEE AGENDA
-
批准号:6267890
-
项目类别:
-
资助金额:$19.13万
-
财政年份:1998
-
负责人:Martin S. Hirsch
-
依托单位:
IMMUNOLOGY AND IMMUNE BASED THERAPY AGENDA
-
批准号:6267887
-
项目类别:
-
资助金额:$19.13万
-
财政年份:1998
-
负责人:Martin S. Hirsch
-
依托单位:
海外基金